Buprenorphine, not methadone, may be safer treatment for opioid-use disorder during pregnancy RutgersU nejm
Opioid agonist therapy is strongly recommended for pregnant persons with opioid use disorder. Buprenorphine may be associated with more favorable neonatal and maternal outcomes than methadone, but existing data are limited.
Delivery by cesarean section occurred in 33.6% of pregnant persons exposed to buprenorphine in early pregnancy and 33.1% of those exposed to methadone , and severe maternal complications developed in 3.3% and 3.5%, respectively Conclusions The use of buprenorphine in pregnancy was associated with a lower risk of adverse neonatal outcomes than methadone use; however, the risk of adverse maternal outcomes was similar among persons who received buprenorphine and those who received methadone.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Structure-based design of bitopic ligands for the µ-opioid receptor - NatureNature - Structure-based design of bitopic ligands for the µ-opioid receptor
Read more »
Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD) | Journal of Clinical OncologyPURPOSE To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. METHODS Participants were adults with advanced cancer and symptom distress (Edmonton Symptom Assessment Scale [ESAS] total score of ≥ 10/90) who received titrated CBD oil 100 mg/mL, 0.5 mL once daily to 2 mL three times a day, or matched placebo for 28 days. The primary outcome was ESAS total symptom distress score (TSDS) at day 14. Response was defined as a decrease in TSDS by ≥ 6 at day 14. Secondary outcomes were ESAS TSDS over time, individual symptom scores, patient-determined effective dose, opioid use, Global Impression of Change, depression, anxiety, quality of life, and adverse events. RESULTS Of the 144 patients randomly assigned, the planned sample size of 58 participants on CBD and 63 on placebo reached the primary analysis point (day 14). The unadjusted change in TSDS from baseline to day 14 was –6.2 (standard deviation, 14.5) for placebo and –3.0 (standard deviation, 15.2) for CBD with no significant difference between arms (P=.24). Similarly, there was no detected difference in proportion of responders (placebo: 37 of 63 [58.7%], CBD: 26 of 58 [44.8%], P=.13). All components of ESAS improved (fell) over time with no difference between arms. The median dose of participant-selected CBD was 400 mg per day with no correlation with opioid dose. There was no detectable effect of CBD on quality of life, depression, or anxiety. Adverse events did not differ significantly between arms apart from dyspnea that was more common with CBD. Most participants reported feeling better or much better at days 14 (53% CBD and 65% placebo) and 28 (70% CBD and 64% placebo). CONCLUSION CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone.
Read more »
Alibaba, Tencent enlisted to help China build RISC-V chipsPRC and chums see open-source chip architecture as safer alternative to Arm
Read more »
'We hope nothing happens to him:' Portugal player asks Qatar to treat pitch invader lenientlyThe Italian protester also displayed supportive messages for Iran and Ukraine, and Wolves midfielder Ruben Neves says he hopes 'the world will understand his message'
Read more »
Piers Corbyn tells councillors “man-made climate change does not exist”… then drives home in beat-up ‘90s Vauxhall CavalierPiers Corbyn tells councillors “man-made climate change does not exist”… then drives home in beat-up 90s Vauxhall Cavalier Corbyn was speaking at an Oxford council meeting on plans for traffic filters designed to “make walking and cycling safer” cycling
Read more »
Twitter is not safer under Elon Musk - and he has made 'alarming changes' to site, former exec warnsYoel Roth resigned from Twitter earlier in November, saying that the platform was starting to stray from adhering to publicly available policies towards decisions made by Elon Musk alone.
Read more »